A new investment firm affiliated with ARCH Venture Partners has raised $200 million for its first fund as it seeks to back scientific research out of Japan to create new global biotech startups.
AN Venture Partners’ financing haul was disclosed in a Thursday SEC filing and comes the same week Osaka-based drugmaker Ono Pharmaceutical said it had doubled its own corporate VC arm to $200 million after having already backed 11 startups, including Photys Therapeutics.
Tokyo and San Francisco-based AN has “an agreed alliance with ARCH,” per the fund’s website, and aims to create new companies and back other early-stage life sciences startups with a focus on science out of Japan. ARCH is one of the most prolific names in the life sciences investment arena, having helped start many blue-chip names in biotech, diagnostics and…
Click here to view original post